CD147, a transmembrane glycoprotein, is expressed on all leukocytes, platelets, and endothelial cells. It has
been implicated in a variety of physiological and pathological activities through interacting with multiple partners, including
cyclophilins, monocarboxylate transporters, Caveolin-1, and integrins. While CD147 is best known as a potent inducer
of extracellular matrix metalloproteinases (hence also called EMMPRIN), it can also function as a key mediator of inflammatory
and immune responses. Increased expression of CD147 has been implicated in the pathogenesis of a number
of diseases, such as asthma-mediated lung inflammation, rheumatoid arthritis, multiple sclerosis, myocardial infarction
and ischemic stroke. Therapeutic targeting of CD147 has yielded encouraging effects in a number of experimental models
of human diseases, suggesting CD147 as an attractive target for treatment of inflammation-related diseases. Here we review
the current understanding of CD147 expression and functions in inflammatory and immune responses and potential
implications for treatment of inflammatory disorders.
Keywords: CD147, MMP, cyclophilin, MCT, integrin, inflammation, leukocyte, platelet.
Rights & PermissionsPrintExport